SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention after a sharp rally and elevated trading activity, with traders pointing to Starknets privacy features, Bitcoin DeFi plans, and post-quantum security as potential catalysts. The reaction is divided between optimism about the projects technology and concerns that the move could be a speculative pump amid token-unlock selling pressure.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

TAO is drawing attention amid a price rebound, with traders highlighting Bittensors decentralized-AI network, limited token supply and staking as reasons for optimism. Others remain cautious about volatility and whether subnet activity can translate into lasting adoption and value for TAO.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RH is drawing attention after a mixed Q2 earnings report and updated outlook; traders are debating whether the strong adjusted earnings result reflects improving business momentum or was materially helped by tariff refunds, with concerns about underlying demand and debt. Bears expect further weakness, while some bulls see the selloff as a buying opportunity and point to potential short-squeeze interest.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is gaining alongside vaccine stocks after reports of an NIH-backed push to accelerate personalized cancer vaccines, though traders note the company and Genentech halted a colorectal cancer vaccine trial after weak efficacy results. The community is also comparing BNTXs move with Modernas stronger rally and debating how much BioNTechs oncology pipeline stands to benefit.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention for choppy consolidation after a rebound, with traders sharing technical setups and debating whether it can break resistance or retreat toward support. Bullish calls tied to broader crypto optimism contrast with concerns that BNB has been weak and the move may fade.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is drawing attention amid a volatile rebound in gold miners after a correction tied to weakness in gold and concerns about higher rates and Treasury yields. Traders are divided on whether the upswing signals a durable turn or a temporary bounce, with some watching for confirmation while others expect further downside.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Attention centers on reported Solana selection of SQD and the broader enterprise-adoption story around its blockchain data-indexing network, with traders also citing Google Cloud and Robinhood integrations. Many are bullish on expanding usage, while others question whether adoption will translate into token value and warn that the volatile move may be speculative; further Google news and a buyback remain speculation.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Cathie Woods portfolio moves and ARKKs track record are driving discussion, with traders criticizing her timing and past underperformance while others point to the funds recent rebound and bullish breakout setups. The debate reflects whether ARKKs concentrated, volatile growth strategy is recovering or remains vulnerable to sharp swings.

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis Inc - Ordinary Shares - Class A

Zoetis is drawing attention after weaker animal-health demand, slowing companion-animal sales and reduced guidance fueled a steep selloff and fresh lows. Traders are split between viewing the decline as an overdone value opportunityoften citing Michael Burrys buyingand arguing that competitive pressure and slowing growth could keep weighing on the stock.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows steep selloff is being discussed in connection with its latest earnings and weaker residential outlook: traders note revenue growth but are concerned that softer housing activity and high mortgage rates are weighing on guidance. Some bulls view the decline as an overreaction to a still-growing business, while bears point to persistent housing-market and competitive pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved

"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved

 Within three months of firing Tracy Beth H?eg, its top drug regulator, the FDA had approved the first mRNA flu shot, cleared a Sanofi diabetes treatment...

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

Equity

Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.

Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights

Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.


Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies

(RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expansion of their global collaboration to develop and commercialize four next-generation, long-acting immunology antibodies targeting type 2 inflammation...

Teva's Branded Drugs Take Center Stage in Its Growth Strategy

Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going

Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.

Full Transcript: Sanofi Q2 2026 Earnings Call

Sanofi (NASDAQ:SNY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.
Benzinga APIs provide real-time access to earningsread more...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Sanofi-Aventis

$SNY they bought $DVAX which supposedly has the best candidate for a plague vaccine. I’m watching this one, considering the events happening in Russia at the moment. 
$QQQ $VOO

Jame Buffalo Bob Gumb

$SNY moves on its own more than almost any Nasdaq large cap. 92.7% of its pairs sit in the weak-correlation zone (-0.3 to 0.3). $AAPL: 22.6%. Data as of Jun 20, 2025. Not advice.

Josh Billings

$SNY  one of the biggest losers in my portfolio. 
At least it still pays a dividend . Looks like new management is needed

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNY Sanofi-Aventis

Fundamentals

Latest SNY News